NYT Editorial Stimulant Warning
It is no longer possible not to notice the lack of medical justification for current psychotropic drug prescribing practices.
Drug Safety Issues: Risks
It is no longer possible not to notice the lack of medical justification for current psychotropic drug prescribing practices.
"This is out-of-control use of drugs that have profound cardiovascular consequences. We have got a potential public health crisis. I think patients and families need to be made aware of these concerns."
"During a hastily called press conference yesterday,” the FDA announced that it is considering ADDITIONAL warnings on the labels of SSRI drugs—Prozac, Paxil, Zoloft, et al.
Children have been dying from exposure to psychostimulant drugs as the FDA looked the other way:
It is astonishing how untrustworthy loosely given advice about the safety of SSRI antidepressants by medical professionals and academic institutions.
"modern pharmacological treatment may be no more beneficial than older ones, despite their added cost."
A major 17-year follow up study published in the British Journal of Psychiatry [1] found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.
By denigrading all non-chemical interventions, by focusing narrowly on drugs and drugs alone, psychiatry has signed away its profession status.
Pharmaceutical News reports that the FDA has issued warnings about diet pills from Brazil marketed as dietary supplements, that contain Prozac and Librium.
In what appears to be a re-run of the Katrina rescue disaster–The New York Times front page report provides yet another example of mindless and heartless shot gun public polices that are being tested on a vulnerable population of citizens:
A Brandeis University study reviewed clinical practice (doctor office visits) and found that drug prescriptions for the treatment of depression, anxiety and mood or attention disorders in teenagers (14 to 18) increased by 250% between 1994-2001.